Literature DB >> 8035946

Albendazole in single CT ring lesions in epilepsy.

M V Padma1, M Behari, N K Misra, G K Ahuja.   

Abstract

Single, small, enhancing lesions that often resolve spontaneously are frequent findings on CTs of Indian patients with seizures. Based on ELISA and biopsy data, the majority of these lesions are probably cysticercosis. To determine if these patients should be treated with albendazole, we performed a double-blind, randomized, placebo-controlled study involving 75 patients with seizures and the appropriate CT abnormality without neurologic abnormality on examination. Patients were randomized to albendazole (15 mg/kg/d) and placebo for 1 week, and we obtained serial CTs at the end of 1 week, 1 month, and 3 months. All patients completed a 3-month follow-up and none had systemic evidence of tuberculosis or cysticercosis. The lesions varied in size from 3 mm to 2.1 cm, with an average size of 1.18 cm. Serum ELISA for cysticercosis was positive in 30 and CSF ELISA was positive in 20 of 45 patients. Forty patients received albendazole and 35 received placebo. At the end of 3 months, a total of 68 patients showed resolution. Thirty-five of 40 patients who received albendazole showed resolution, as opposed to 33 of 35 patients on placebo. We conclude that albendazole therapy was not beneficial.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035946     DOI: 10.1212/wnl.44.7.1344

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

Review 2.  Controversies in the management of cysticercosis.

Authors:  C Evans; H H Garcia; R H Gilman; J S Friedland
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

3.  A diagnostic and therapeutic scheme for a solitary cysticercus granuloma.

Authors:  G Singh; V Rajshekhar; J M K Murthy; S Prabhakar; M Modi; N Khandelwal; H H Garcia
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

4.  Neurocysticercosis: an update.

Authors:  Christina M Coyle
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

Review 5.  Anthelmintics for people with neurocysticercosis.

Authors:  Katharine Abba; Sridharan Ramaratnam; Lakshmi Narasimhan Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 6.  Treatment of neurocysticercosis: current status and future research needs.

Authors:  T E Nash; G Singh; A C White; V Rajshekhar; J A Loeb; J V Proaño; O M Takayanagui; A E Gonzalez; J A Butman; C DeGiorgio; O H Del Brutto; A Delgado-Escueta; C A W Evans; R H Gilman; S M Martinez; M T Medina; E J Pretell; J Teale; H H Garcia
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

Review 7.  Neurocysticercosis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

Review 8.  Taenia solium cysticercosis.

Authors:  Héctor H García; Armando E Gonzalez; Carlton A W Evans; Robert H Gilman
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

Review 9.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Diagnosis and treatment of neurocysticercosis.

Authors:  Christina M Coyle; Herbert B Tanowitz
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.